Evidence map›Paper›PMID 29056009›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2017

[Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B].

D C Cai, C Pan, W H Yu, S S Dang, J Li, S M Wu, N Jiang, M R Wang, Z H Zhang, F Lin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Alanine aminotransferase normalization with antiviral therapies in hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

D C CaiThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
C PanMengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350000, China.
W H YuThe Eighth People's Hospital of Guangzhou, Guangzhou 510060, China.
S S DangThe Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
J LiThe Second People's Hospital of Tianjin, Tianjin 300192, China.
S M WuShanghai Public Health Clinical Center, Shanghai 201508, China.
N JiangSichuan Provincial People's Hospital, Chengdu 610772, China.
M R WangNo.81 Hospital of PLA, Nanjing 210002, China.
Z H ZhangJinan Infectious Disease Hospital, Jinan 250021, China.
F LinHainan General Hospital, Haikou 570311, China.
S J XinNo.302 Hospital of PLA, Beijing 100039, China.
Y F YangThe Second Hospital of Nanjing, Nanjing 210003, China.
B S ShenThe First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China.
H RenThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiviral AgentsCapsulesDNA, ViralGuanineHepatitis B, ChronicHepatitis B e AntigensHepatitis B virusHumansTreatment OutcomeAntiviral AgentsCapsulesDNA, ViralentecavirGuanineHepatitis B e AntigensEfficacyEntecavir capsuleSafety

Identifiers

PMID29056009
PMCPMC12769142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.